Vitaly Margulis, MD, UT Southwestern Medical Center, walks through the ENLIGHTED trial interim analysis.
Upper Tract Urothelial Carcinoma
Advertisement
Latest News
Surgical resection of the primary tumor can provide survival benefits in certain patients with metastatic UTUC.
Drs. Roupret and Houede dissect their research on the safety and efficacy of durvalumab with NAC for operable high-risk UTUC.
Dr. Murray and Laura Bauer share their experiences treating patients with UTUC using mitomycin gel.
Patients who achieved a complete response after six doses of UGN-101 were followed up for 12 months after initial CR.
Dr. Hafron breaks down the most important updates in upper tract urothelial carcinoma from the LUGPA 2024 Annual Meeting.
Drs. Michael Whalen and Vincent Xu discuss potential alternative treatments for patients who are ineligible for chemotherapy.
Drs. Michael Whalen and Vincent Xu discuss their recent analysis of neoadjuvant chemotherapy utilization for UTUC.
Drs. Sundaram and Murray highlight the results of a study on robotic nephroureterectomy and bladder cuff excision for UTUC.
Drs. Gupta and Kohlmann focus on the prevalence of pathogenic variants in the urethra, upper tract, and bladder.
Drs. Gupta and Kohlmann discuss why comprehensive germline testing is crucial for accurate diagnosis and treatment of UTUC.
Roundtable Discussions
The panel offers concluding thoughts on selection criteria for lymph node dissection in patients with low-grade UTUC.
The panel dissects a longitudinal follow-up of a multicenter study of UGN-101 as well as other 2024 AUA meeting data.
The panel considers how to best treat patients with low-grade UTUC who experience disease recurrence post-surgery.
The panel highlights nephron-sparing approaches as well as current treatment pathways for low-grade UTUC.
The panel provides a disease state overview of low-grade UTUC, including considerations for diagnosis, staging, and grading.
The panel engages in a discussion related to risk stratification in UTUC, including identification of high-risk patients.
Urothelial Cancer Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Advertisement
Advertisement
Trending
Dr. Faltas highlights CLONEVO, a trial using preoperative abemaciclib in cisplatin-ineligible MIBC with ctDNA monitoring.
Dr. Hayne speaks about the ANZUP 101 trial results that evaluated the combination of mitomycin and BCG for NMIBC.
BCG plus mitomycin may be an alternative treatment for patients with high-risk NMBIC as access to BCG is limited worldwide.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.